ArticleHepatology (Baltimore, Md.)2020
Intestinal Virome in Patients With Alcoholic Hepatitis.
Article in Hepatology (Baltimore, Md.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 96 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
96 citing papers in PubMed, 138 citations in OpenAlex.
- Emerging biotechnological approaches in alcoholic liver disease: natural compounds, delivery systems, and translational potential.Science China. Life sciences · 2026Review
- Gut Microbiota and Ageing: A Critical Crosstalk in Alcohol-Related Liver Disease.Microorganisms · 2026Review
- The gut-liver axis in drug-induced liver injury (DILI): Interplay between gut microbiota, intestinal barrier, and immune system.Acta pharmaceutica Sinica. B · 2026Review
- Optimizing methods for virome analysis based on studies of a synthetic viral community.mSystems · 2026Article
- Alternating High-Fat and Polysaccharide Diets Modulates Gut Phage-Bacterial Interplay.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Peptide YY reduces cytotoxicity of Candida albicans in alcohol-associated liver disease.JHEP reports : innovation in hepatology · 2026Article
- Bifidobacterium bifidum-derived nanoparticles attenuate alcoholic liver disease via enhanced hepatic phagocytosis and gastrointestinal homeostasis.Nature communications · 2026Article
- Gut microbiome and bile acid metabolism in liver disease: Mechanisms, clinical implications, and therapeutic opportunities.Pharmacological reviews · 2026Review
- Enhanced multi-omic viral profiling from microbial community sequencing with BAQLaVa.bioRxiv : the preprint server for biology · 2026Article
- Gut virome dynamics: from commensal to critical player in health and disease.Nature reviews. Gastroenterology & hepatology · 2026Review
- Antiviral Drugs in HIV and Cardiovascular Disease: Mechanistic Insights and Clinical Implications.Pharmaceuticals (Basel, Switzerland) · 2026Review
- The gut-liver-immune axis: structural basis, cellular architecture, molecular mediators, and disease-specific manifestations.Frontiers in immunology · 2026Review
- Gut microbiome in alcohol-associated liver disease: interactions and therapeutic strategies.Frontiers in pharmacology · 2026Review
- Article
- Clinical and biological significance of the relationship between gut microbiota and liver disease.World journal of hepatology · 2025Review
- Identification and characterization of a novel plaque-invisible lytic single-stranded RNA phage.Journal of virology · 2025Article
- Review
- Optimizing methods for virome analysis based on studies of a synthetic viral community.bioRxiv : the preprint server for biology · 2025Article
- Compositional and Metabolomic Shifts of the Gut Microbiome in Alcohol-Related Liver Disease.Journal of gastroenterology and hepatology · 2025Review
- Immune Modulation by Microbiota and Its Possible Impact on Polyomavirus Infection.Pathogens (Basel, Switzerland) · 2025Review
36 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors at 14 institutions in 8 countries.
Funding
Abstract
BACKGROUND AND
aimsAlcoholic hepatitis (AH) is a severe manifestation of alcohol-associated liver disease (ALD) with high mortality. Although gut bacteria and fungi modulate disease severity, little is known about the effects of the viral microbiome (virome) in patients with ALD. APPROACH AND
resultsWe extracted virus-like particles from 89 patients with AH who were enrolled in a multicenter observational study, 36 with alcohol use disorder (AUD), and 17 persons without AUD (controls). Virus-like particles from fecal samples were fractionated using differential filtration techniques, and metagenomic sequencing was performed to characterize intestinal viromes. We observed an increased viral diversity in fecal samples from patients with ALD, with the most significant changes in samples from patients with AH. Escherichia-, Enterobacteria-, and Enterococcus phages were over-represented in fecal samples from patients with AH, along with significant increases in mammalian viruses such as Parvoviridae and Herpesviridae. Antibiotic treatment was associated with higher viral diversity. Specific viral taxa, such as Staphylococcus phages and Herpesviridae, were associated with increased disease severity, indicated by a higher median Model for End-Stage Liver Disease score, and associated with increased 90-day mortality.
conclusionsIn conclusion, intestinal viral taxa are altered in fecal samples from patients with AH and associated with disease severity and mortality. Our study describes an intestinal virome signature associated with AH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.